Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2017-10-05 Regulatory Filings
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Zawarcie umowy na budowę Centrum Badawczo - Rozwojowego - Content (PL)
Regulatory Filings Classification · 95% confidence The document discusses the execution of a general contractor agreement (Umowa o generalne wykonawstwo) for the construction of a Research and Development Center (CBR). It details the contract value (29.6 million PLN net), the scope of work (shell construction, internal installations, external works), and terms regarding penalties (kary umowne). This content relates to a significant business operation, contract award, or financing/capital expenditure activity, but it is not a standard regulatory filing like 10-K, ER, or IR. It is a specific announcement regarding a major contract execution. Given the options, this type of specific business update, which is material but doesn't fit the core financial reports (10-K, IR, ER) or governance/shareholder events (AGM, DVA), is best classified as a general Regulatory Filing (RNS) as it is a specific, material announcement not covered by other codes, or potentially CAP if viewed as a major capital expenditure commitment. However, RNS is the most appropriate fallback for specific, material, non-standard announcements in this context, especially since it references a prior 'raport bieżący' (current report). Since it details a major contract award, it is a significant business event announcement.
2017-10-05 Polish
Złożenie wniosku o zgodę na rozpoczęcie fazy klinicznej badań nad lekiem opartym na S-ketaminie - Content (PL)
Regulatory Filings Classification · 95% confidence The document text discusses an update regarding the development of a drug (S-ketamine) by Celon Pharma S.A. Specifically, it mentions filing an application with the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products to start the clinical phase of drug trials. This relates to the company's ongoing projects, research, and potential future revenue streams, but it is not a standard financial report (10-K, IR, ER) or a management change (MANG). It is an announcement concerning a significant operational/development milestone, which often falls under general regulatory announcements or specific project updates. Given the options, this is a specific operational update related to product development and regulatory progress. Since there is no specific code for 'R&D Update' or 'Regulatory Application Filing', and it is a formal announcement to the market regarding a significant step in a development project, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous, material, non-financial announcement, or potentially 'LTR' if viewed as a regulatory interaction, but RNS is the broader fallback for material non-standard announcements. Given the context of Polish regulatory filings, this is a 'raport bieżący' (current report), which maps best to RNS.
2017-09-29 Polish
Zawarcie umowy z Pure Biologics Sp. z o.o. w zakresie realizacji Projektu TNBC. - Content (PL)
Regulatory Filings Classification · 93% confidence The document text describes the signing of a contract (umowa) between GLG Pharma S.A. and Pure Biologics Sp. z o.o. for the supply of antibodies related to a diagnostic test for a clinical trial. It details the subject matter, completion date (31.12.2017), and value (0.8 million PLN). This type of announcement, detailing a significant business transaction or contract, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate governance filings (like DEF 14A, DIRS). It is a material business event announcement. Given the available options, the most appropriate general category for a significant, non-standard regulatory disclosure that isn't explicitly covered elsewhere (like M&A or financing) is the general 'Regulatory Filings' fallback category (RNS), as it is a mandatory disclosure of a material contract in the Polish market context, often filed via similar channels as RNS announcements in other jurisdictions.
2017-09-22 Polish
CELON_RAPORT_HY2017_FINAL_InformacjaDodatkowa.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Informacja dodatkowa do skróconego śródrocznego sprawozdania finansowego' (Additional information to the condensed interim financial report) for Celon Pharma S.A. for the first half of 2017. It contains detailed accounting policies, notes to the financial statements, and breakdowns of balance sheet items. As it provides substantive financial data and analysis for an interim period (H1 2017), it qualifies as an Interim/Quarterly Report. H1 2017
2017-09-21 Polish
CELON_RAPORT_HY2017_SprawozdanieZarzadu.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Sprawozdanie Zarządu z działalności Celon Pharma S.A. w I półroczu 2017 roku' (Management Board Report on the activities of Celon Pharma S.A. in the first half of 2017). It contains detailed financial data, balance sheets, cash flow statements, and management commentary for a period shorter than a full fiscal year (H1 2017). It is a comprehensive report rather than a brief announcement, fitting the definition of an Interim/Quarterly Report. H1 2017
2017-09-21 Polish
CELON_RAPORT_HY2017_OswiadczeniePodmiot.pdf
Audit Report / Information Classification · 95% confidence The document is a formal declaration ('OŚWIADCZENIE ZARZĄDU') from the Management Board of Celon Pharma S.A. regarding the entity authorized to audit the financial statements and review the semi-annual condensed financial statement. This declaration confirms compliance with legal requirements for the auditor/reviewer. This content relates specifically to the audit process and the qualifications of the auditor, which aligns best with the 'Audit Report / Information' category, as it discusses the entity responsible for the audit/review, even though it is not the audit report itself. Given the short length (605 chars) and the nature of the declaration concerning the auditor's qualifications for reviewing the semi-annual report, it fits the scope of AR (Audit Report / Information) better than a general RNS or RPA, as it is a specific regulatory compliance statement about the audit function. H1 2017
2017-09-21 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.